Jason Kellogg, MD

Articles by Jason Kellogg, MD

Defining and Treating Agitation in Alzheimer Disease, With Jason Kellogg, MD

July 28th 2026

Consensus definition clarifies Alzheimer agitation, reviews FDA-approved brexpiprazole and dextromethorphan-bupropion, and spotlights caregiver burden

Neuroplasticity, Novel Targets, and the Future of Depression Pharmacotherapy

ByJason Kellogg, MD

July 27th 2026

Explore next-gen depression therapies targeting neuroplasticity and why biomarkers may unlock precision psychiatry for MDD.

Potential of GABAergic Medications in MDD

ByGustavo Alva, MD, DFAPA,Jason Kellogg, MD

July 2nd 2026

Expert explores fast-acting depression treatments, psilocybin trial pitfalls, and why stigma still limits buprenorphine access for opioid use disorder.